FDA Clearance Tracker · P200015-S077
SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 27, 2026
Approved
Time to decision
180 days
Received Apr 30, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
The decision
- FDA number
- P200015-S077
- Device name
- SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Apr 30, 2026
- Decided
- Oct 27, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P200015
Device type
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for a design modification to the outflow apices of the Alterra prestent.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.